Manila Times Business
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial utilizes novel sequential treatment approach designed to combine rapid symptom control of FcRn inhibition with sustained disease modification of B-cell depletion therapy NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the "Company” or "TG Therapeutics
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bata, Django, De la Cruz lead coaching staff of new billiards NSA
2h ago
Tokenized Cash Management Advisory Group Publishes the Scope of Its Work Program
2h ago
COSMOBEAUTÉ MALAYSIA & BEAUTYEXPO 2026 RETURNS TO KLCC TO DRIVE B2B EXCELLENCE AND NEW BUSINESS FRONTIERS
2h ago
Regent Hong Kong Named Among First-Ever Winners of Condé Nast Traveler's Triple Crown Award
2h ago